Application of a multidisciplinary approach to Alzheimer's disease to develop novel drug targets by integrating biomarkers, imaging, genetic and molecular strategies

Current Alzheimer Research

Volumn 8, Issue 1, 2011, Pages 1-3

  Lahiri, Debomoy K ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DIMEBON; IMMUNOGLOBULIN; NOOTROPIC AGENT; ROSIGLITAZONE; SEMAGACESTAT;

ALZHEIMER DISEASE; EDITORIAL; HUMAN; IMMUNIZATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT FAILURE;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DATABASES, BIBLIOGRAPHIC; DIAGNOSTIC IMAGING; DRUG DESIGN; GENETICS; HUMANS;

EID: 79951760462     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720511794604534     Document Type: Editorial

References (29)

1. Alzheimr's Research Forum, http://www.alzforum.org/ (accessed on 1/23/2011)
2. Lahiri, D.K. Editorial: 'Current Alzheimer Research' helps accelerate the progress of the field. Curr Alzheimer Res 7(1):1-2 (2010).
3. Shineman DW, Fillit HM. Alzheimer's disease drug discovery: Abeta and beyond. Curr Alzheimer Res 1;7(3):188-9 (2010).
4. Lahiri DK. Editorial--"Current aging science": an important platform for reporting advances in aging-related research. Curr Aging Sci 3(1):1-2 (2010).
5. Hock BJ, Lattal KM, Kulnane LS, Abel T, Lamb BT. Pathology associated memory deficits in Swedish mutant genome-based amyloid precursor protein transgenic mice. Curr Aging Sci 2(3): 205-13 (2009).
6. Sato N, Takeda S, Uchio-Yamada K, Ueda H, Fujisawa T, Rakugi H, et al. Role of Insulin Signaling in the Interaction Between Alzheimer Disease and Diabetes Mellitus: A Missing Link to Therapeutic Potential. Curr Aging Sci Jan 14, 2011. [Epub ahead of print] PMID: 21235496
7. Del Carmen Alonso A. Tau, neurodegeneration and Alzheimer's disease. Curr Alzheimer Res 7(8): 653-5 (2010).
8. Alzheimer's Association, http://www.alz.org/news_and_events_ Obama_signs_NAPA.asp (accessed on 1/23/2011)
9. Alzheimer's Association, http://www.alz.org/documents/national/ Federal_Priorities_2010.pdf (accessed on 1/24/2011)
10. Schneider LS. Fixing Alzheimer disease trials by improving process and methods. Curr Alzheimer Res 7(7): 564-5 (2010).
11. Becker RE, Greig NH. Why so few drugs for Alzheimer's disease? Are methods failing drugs? Curr Alzheimer Res 7(7): 642-51 (2010).
12. Maher-Edwards G, Zvartau-Hind M, Hunter AJ, Gold M, Hopton G, Jacobs G, et al. Double-blind, controlled phase II study of a 5- HT6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr Alzheimer Res 7(5): 374-85 (2010).
13. Spies PE, Slats D, Sjögren JM, Kremer BP, Verhey FR, Rikkert MG, et al. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res 7(5): 470-6 (2010).
14. Kim S, Jensen JR, Cisek K, Funk KE, Naphade S, Schafer K, et al. Imaging as a strategy for premortem diagnosis and staging of tauopathies. Curr Alzheimer Res 7(3):230-4 (2010).
15. Forsberg A, Almkvist O, Engler H, Wall A, Långström B, Nordberg A. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 7(1): 56-66 (2010).
16. Augelli-Szafran CE, Wei HX, Lu D, Zhang J, Gu Y, Yang T, et al. Discovery of notch-sparing gamma-secretase inhibitors. Curr Alzheimer Res 7(3):207-9 (2010).
17. Parri RH, Dineley TK. Nicotinic acetylcholine receptor interaction with beta-amyloid: molecular, cellular, and physiological consequences. Curr Alzheimer Res 7(1): 27-39 (2010).
18. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer Disease and related Tauopathies. Curr Alzheimer Res 7(8): 656-64 (2010).
19. Duff K, Kuret J, Congdon EE. Disaggregation of tau as a therapeutic approach to tauopathies. Curr Alzheimer Res 7(3): 235-40 (2010).
20. Darvesh S, Reid GA, Martin E. Biochemical and histochemical comparison of cholinesterases in normal and Alzheimer brain tissues. Curr Alzheimer Res 7(5): 386-400 (2010).
21. Bailey JA, Lahiri DK. A novel effect of rivastigmine on presynaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem 112(4): 843-53 (2010).
22. Reddy PH. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol 218(2): 286-92 (2009).
23. Ray B, Bisht S, Maitra A, Maitra A, Lahiri DK. Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc™) in the neuronal cell culture and animal model: Implications for Alzheimer's Disease. J Alzheimers Dis 23(1): 61-77 (2011).
24. Lahiri DK, Maloney B, Zawia NH. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 14(11): 992-1003 (2009).
25. Dantuma E, Merchant S, Sugaya K. Stem cells for the treatment of neurodegenerative diseases. Stem Cell Res Ther 1(5): 37 (2010).
26. Dauwels J, Vialatte F, Cichocki A. Diagnosis of Alzheimer's disease from EEG signals: where are we standing? Curr Alzheimer Res 7(6): 487-505 (2010).
27. Sokol DK, Chen D, Farlow MR, Dunn DW, Maloney B, Zimmer JA, et al. High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J Child Neurol 21(6): 444-9 (2006).
28. Malter JS, Ray BC, Westmark PR, Westmark CJ. Fragile X Syndrome and Alzheimer's Disease: Another story about APP and beta-amyloid. Curr Alzheimer Res 7(3): 200-6 (2010).
29. Lahiri DK. An integrated approach to genome studies. Science 331(6014): 147 (2011).